Logo image
Development of novel nucleic acid technologies for tackling neurological diseases
Doctoral Thesis   Open access

Development of novel nucleic acid technologies for tackling neurological diseases

Madhuri Chakravarthy
Doctor of Philosophy (PhD), Murdoch University
2019
pdf
Chakravarthy20191.pdfDownloadView
Whole Thesis Open Access

Abstract

Nucleic acid technologies such as antisense oligonucleotides (AOs) and DNAzymes can bind specifically to target messenger RNA and modulate gene expression by different mechanisms of actions. Recent approval of Nusinersen (Spinraza), by the United States Food and Drug Administration for the treatment of spinal muscular atrophy has demonstrated the potential of nucleic acid technologies in treatment of neuromuscular diseases. This thesis explores the potential of AOs and DNAzymes for tackling neurological diseases, particularly multiple sclerosis and Alzheimer’s disease. Chapter 1 provides a broad overview of the various nucleic acid technologies including the importance of chemical modifications and delivery of the nucleic acid molecules for clinical applications. Chapter 2 focused on developing DNAzymes targeting integrin subunit alpha 4 (ITGA4), a validated therapeutic target in multiple sclerosis. A DNAzyme candidate, RNV143, was identified to efficiently cleave exon 9 of ITGA4 RNA. This chapter also briefly explored the use of chemical modifications for nuclease resistance. Towards this, the DNAzyme, RNV143 was chemically modified and further evaluated for its nuclease resistance and cleavage activity. The focus of Chapter 3 was to develop DNAzyme and splice modulating AOs for tackling Alzheimer’s Disease by targeting amyloid precursor protein (APP), beta-site amyloid precursor protein cleaving enzyme (BACE1), and microtubule-associated protein tau (MAPT). Splice modulating AOs targeting APP, BACE1, and MAPT were developed and evaluated at the RNA and protein levels. DNAzymes targeting MAPT were also developed and its efficacy was evaluated in vitro. The results presented here highlight the scope of DNAzymes and splice modulating AOs for tackling multiple sclerosis and Alzheimer’s disease.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Metrics

123 File views/ downloads
156 Record Views
Logo image